This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Evans, S. M. Articles by Koch, C. J. Search for Related Content PubMed PubMed Citation Articles by Evans, S. M. Articles by Koch, C. J.

Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors

Departments of ¹ Radiation Oncology, ² Neurosurgery, ³ Biostatistics, and ⁴ Pathology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

We investigated whether increasing levels of tissue hypoxia, measured by the binding of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] or by Eppendorf needle electrodes, were associated with tumor aggressiveness in patients with previously untreated glial brain tumors. We hypothesized that more extensive and severe hypoxia would be present in tumor cells from patients bearing more clinically aggressive tumors. Hypoxia was measured with the 2-nitroimidazole imaging agent EF5 in 18 patients with supratentorial glial neoplasms. In 12 patients, needle electrode measurements were made intraoperatively. Time to recurrence was used as an indicator of tumor aggression and was analyzed as a function of EF5 binding, electrode values and recursive partitioning analysis (RPA) classification. On the basis of EF5 binding, WHO grade 2 tumors were characterized by modest cellular hypoxia (pO₂s 10%) and grade 3 tumors by modest-to-moderate hypoxia (pO₂s 10%- 2.5%). Severe hypoxia (0.1% oxygen) was present in 5 of 12 grade 4 tumors. A correlation between more rapid tumor recurrence and hypoxia was demonstrated with EF5 binding, but this relationship was not predicted by Eppendorf measurements.

This article has been cited by other articles:

				A. M. Spence, M. Muzi, K. R. Swanson, F. O'Sullivan, J. K. Rockhill, J. G. Rajendran, T. C.H. Adamsen, J. M. Link, P. E. Swanson, K. J. Yagle, et al. Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival Clin. Cancer Res., May 1, 2008; 14(9): 2623 - 2630. [Abstract] [Full Text] [PDF]

				M. Takasawa, R. R. Moustafa, and J.-C. Baron Applications of Nitroimidazole In Vivo Hypoxia Imaging in Ischemic Stroke Stroke, May 1, 2008; 39(5): 1629 - 1637. [Abstract] [Full Text] [PDF]

				N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms. Cancer Res., March 15, 2006; 66(6): 3197 - 3204. [Abstract] [Full Text] [PDF]

				D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]

				D. Vordermark, S. M. Evans, S. M. Hahn, K. D. Judy, and C. J. Koch Significance of Hypoxia in Malignant Glioma. Re: Evans et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84 Clin. Cancer Res., May 15, 2005; 11(10): 3966 - 3968. [Full Text] [PDF]